UA46001C2 - Кристалічний гідрохлорид валацикловіру (варіанти), спосіб одержання кристалічного валацикловіру та спосіб лікування людини від інфекційного захворювання, спричиненого вірусом герпесу - Google Patents

Кристалічний гідрохлорид валацикловіру (варіанти), спосіб одержання кристалічного валацикловіру та спосіб лікування людини від інфекційного захворювання, спричиненого вірусом герпесу Download PDF

Info

Publication number
UA46001C2
UA46001C2 UA97084268A UA97084268A UA46001C2 UA 46001 C2 UA46001 C2 UA 46001C2 UA 97084268 A UA97084268 A UA 97084268A UA 97084268 A UA97084268 A UA 97084268A UA 46001 C2 UA46001 C2 UA 46001C2
Authority
UA
Ukraine
Prior art keywords
valacyclovir
hydrochloride
valacyclovir hydrochloride
fact
solvent
Prior art date
Application number
UA97084268A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Баррі Говард Картер
Джейн М'юз Партін
Пітер Грегорі Варлашкін
Річард Огастас Вінніке
Вільям Бейн ІІІ Грабб
Грегорі Алан Конвей
Філіп Джордж Лейк
Дейвід Майкл Скіннер
Дейвід Джеймз Вотроп
Original Assignee
Зе Веллкам Фаундейшн Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA46001(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Зе Веллкам Фаундейшн Лімітед filed Critical Зе Веллкам Фаундейшн Лімітед
Publication of UA46001C2 publication Critical patent/UA46001C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
UA97084268A 1995-01-20 1996-01-19 Кристалічний гідрохлорид валацикловіру (варіанти), спосіб одержання кристалічного валацикловіру та спосіб лікування людини від інфекційного захворювання, спричиненого вірусом герпесу UA46001C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (1)

Publication Number Publication Date
UA46001C2 true UA46001C2 (uk) 2002-05-15

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97084268A UA46001C2 (uk) 1995-01-20 1996-01-19 Кристалічний гідрохлорид валацикловіру (варіанти), спосіб одержання кристалічного валацикловіру та спосіб лікування людини від інфекційного захворювання, спричиненого вірусом герпесу

Country Status (40)

Country Link
US (1) US6107302A (en, 2012)
EP (1) EP0804436B1 (en, 2012)
JP (1) JP3176633B2 (en, 2012)
KR (1) KR100376074B1 (en, 2012)
CN (1) CN1049893C (en, 2012)
AP (1) AP662A (en, 2012)
AR (1) AR002270A1 (en, 2012)
AT (1) ATE302777T1 (en, 2012)
AU (1) AU702794B2 (en, 2012)
BG (1) BG63393B1 (en, 2012)
BR (1) BR9606768A (en, 2012)
CA (1) CA2210799C (en, 2012)
CY (1) CY2531B1 (en, 2012)
CZ (1) CZ297065B6 (en, 2012)
DE (1) DE69635106T2 (en, 2012)
DK (1) DK0804436T3 (en, 2012)
EA (1) EA000364B1 (en, 2012)
EE (1) EE03528B1 (en, 2012)
ES (1) ES2248806T3 (en, 2012)
FI (1) FI973063L (en, 2012)
GB (1) GB9501178D0 (en, 2012)
GE (1) GEP20001940B (en, 2012)
HR (1) HRP960024B1 (en, 2012)
HU (1) HU222993B1 (en, 2012)
IL (1) IL116831A (en, 2012)
IN (1) IN182468B (en, 2012)
IS (1) IS2268B (en, 2012)
NO (1) NO315558B1 (en, 2012)
NZ (1) NZ298851A (en, 2012)
OA (1) OA10499A (en, 2012)
PL (1) PL182175B1 (en, 2012)
RO (1) RO118693B1 (en, 2012)
RS (1) RS49518B (en, 2012)
SI (1) SI0804436T1 (en, 2012)
SK (1) SK285329B6 (en, 2012)
TR (1) TR199700656T1 (en, 2012)
UA (1) UA46001C2 (en, 2012)
UY (1) UY25779A1 (en, 2012)
WO (1) WO1996022291A1 (en, 2012)
ZA (1) ZA96449B (en, 2012)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
ATE254463T1 (de) * 1996-01-19 2003-12-15 Glaxo Group Ltd Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
EP0976750A4 (en) * 1997-01-17 2001-05-30 Ajinomoto Kk NEW Z-VALACYCLOVIR CRYSTALS
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
DK2298769T3 (da) * 2001-02-24 2014-01-20 Boehringer Ingelheim Pharma Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel
MXPA04002192A (es) * 2001-09-07 2005-02-17 Teva Pharma Formas cristalinas de clorhidrato de valaciclovir.
WO2003040145A1 (en) * 2001-11-05 2003-05-15 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CA2649826A1 (en) * 2001-11-14 2003-05-22 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
WO2004000265A2 (en) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) * 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
WO2004052892A1 (en) * 2002-12-09 2004-06-24 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
WO2005000850A2 (en) * 2003-06-02 2005-01-06 Teva Pharmaceutical Industries, Ltd. Novel crystalline forms of valacyclovir hydrochloride
KR20060117355A (ko) * 2004-01-21 2006-11-16 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로버 염산염의 제조 방법
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
EP1891071B1 (en) * 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
KR101541791B1 (ko) * 2006-05-04 2015-08-04 베링거 인겔하임 인터내셔날 게엠베하 다형태
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
RU2569749C2 (ru) * 2007-08-17 2015-11-27 Бёрингер Ингельхайм Интернациональ Гмбх Производные пурина, предназначенные для применения для лечения заболеваний, связанных с баф (белок-активатор фибробластов)
WO2009031576A1 (ja) * 2007-09-03 2009-03-12 Ajinomoto Co., Inc. バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
AR071175A1 (es) 2008-04-03 2010-06-02 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
WO2010018217A2 (en) * 2008-08-15 2010-02-18 Boehringer Ingelheim International Gmbh Organic compounds for wound healing
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR20110103968A (ko) 2008-12-23 2011-09-21 베링거 인겔하임 인터내셔날 게엠베하 유기 화합물의 염 형태
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
KR20190071840A (ko) 2009-11-27 2019-06-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
AU2011268940B2 (en) 2010-06-24 2015-05-21 Boehringer Ingelheim International Gmbh Diabetes therapy
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013076688A1 (en) * 2011-11-25 2013-05-30 Piramal Enterprises Limited A process for the preparation of valacyclovir hydrochloride
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
US5831075A (en) * 1993-06-10 1998-11-03 Rolabo Sl Amino acid ester of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
CA2210799C (en) 2008-06-10
EP0804436B1 (en) 2005-08-24
KR100376074B1 (ko) 2003-06-02
PL321326A1 (en) 1997-12-08
HUP9801836A3 (en) 1999-06-28
GEP20001940B (en) 2000-02-05
OA10499A (en) 2002-04-10
AU702794B2 (en) 1999-03-04
ZA96449B (en) 1996-08-07
IS2268B (is) 2007-07-15
WO1996022291A1 (en) 1996-07-25
NZ298851A (en) 1999-01-28
AU4453996A (en) 1996-08-07
EE03528B1 (et) 2001-10-15
CN1179159A (zh) 1998-04-15
SI0804436T1 (sl) 2006-02-28
GB9501178D0 (en) 1995-03-08
ES2248806T3 (es) 2006-03-16
EA000364B1 (ru) 1999-06-24
NO315558B1 (no) 2003-09-22
BG101833A (bg) 1998-04-30
KR19980701525A (ko) 1998-05-15
DK0804436T3 (da) 2005-12-27
EA199700124A1 (ru) 1997-12-30
PL182175B1 (pl) 2001-11-30
US6107302A (en) 2000-08-22
TR199700656T1 (xx) 1998-03-21
NO973326D0 (no) 1997-07-18
SK96597A3 (en) 1998-02-04
EE9700175A (et) 1998-02-16
HRP960024B1 (en) 2005-08-31
SK285329B6 (sk) 2006-11-03
FI973063A7 (fi) 1997-09-18
EP0804436A1 (en) 1997-11-05
JP3176633B2 (ja) 2001-06-18
BR9606768A (pt) 1997-12-30
HUP9801836A2 (hu) 1999-05-28
AR002270A1 (es) 1998-03-11
CA2210799A1 (en) 1996-07-25
IL116831A0 (en) 1996-05-14
AP9701058A0 (en) 1997-10-31
ATE302777T1 (de) 2005-09-15
RO118693B1 (ro) 2003-09-30
HRP960024A2 (en) 1997-10-31
NO973326L (no) 1997-09-16
DE69635106T2 (de) 2006-06-08
FI973063L (fi) 1997-09-18
DE69635106D1 (de) 2005-09-29
MX9705462A (es) 1997-10-31
AP662A (en) 1998-08-19
JPH11503718A (ja) 1999-03-30
IN182468B (en, 2012) 1999-04-17
IS4527A (is) 1997-07-15
CY2531B1 (en) 2006-04-12
FI973063A0 (fi) 1997-07-18
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
YU3396A (sh) 1998-12-23
HU222993B1 (hu) 2004-01-28
CZ297065B6 (cs) 2006-08-16
CZ229497A3 (en) 1997-12-17
UY25779A1 (es) 2000-08-21
IL116831A (en) 1998-10-30
RS49518B (sr) 2006-10-27

Similar Documents

Publication Publication Date Title
UA46001C2 (uk) Кристалічний гідрохлорид валацикловіру (варіанти), спосіб одержання кристалічного валацикловіру та спосіб лікування людини від інфекційного захворювання, спричиненого вірусом герпесу
KR100412298B1 (ko) 콜로이드이산화규소를함유하는발라시클로비르정제
KR20010074472A (ko) 신규의 결정질 형태의 항바이러스성 벤즈이미다졸 화합물
CA2243237C (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
EA002953B1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(β-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
ES2324281T3 (es) Eteres de dicarboxilato de calcio, procedimientos de fabricacion de los mismos.
MXPA97005462A (en) Derived from guan
HK1003055A1 (en) Guanine derivative
HK1003055B (en) Guanine derivative
MXPA97005459A (en) Valaciclovir tablets containing silicon dioxide color